ACE2: More of Ang-(1-7) or less Ang II?

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 1, 2011, Pages 1-6

  Ferrarlo, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin peptides; Angiotensin converting enzyme 2; Essential hypertension; Renal disease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VASODILATATION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; HUMANS; HYPERTENSION; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 79851511993     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283406f57     Document Type: Article

References (80)

1. Chappell MC, Welches WR, Brosnihan KB, Ferrario CM. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate. Peptides 1992; 13:943-946.
2. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993; 52:1461-1480.
3. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
4. Turner AJ, Tipnis SR, Guy JL, et al. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue ofangiotensin-converting enzyme insensitiv (Pubitemid 34451252)
5. Nagata S, Kato J, Sasaki K, et al. Isolation and identification of proangiotensin-12, a possible componentofthe renin-angiotensin system. Biochem Biophys Res Commun 2006; 350:1026-1031. (Pubitemid 44596223)
6. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 2008; 294:H2242-H2247.
7. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005; 289: H2281-H2290. (Pubitemid 41698533)
8. Ferrario CM, Varagic J, Habibi J, et al. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 2009; 296:H1184-H1192.
9. Ferrario CM, Varagic J. The ANG-(1 -7)/ACE2/Mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 2010; 298:F1297-F1305.
10. Santos RA, Simoes E, Silva AC, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100:8258-8263. (Pubitemid 36842532)
11. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006; 47:996-1002. (Pubitemid 44297574)
12. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 2005; 289:H1560-H1566. (Pubitemid 41368998)
13. Bunnemann B, Fuxe K, Metzger R, et al. Autoradiographic localization of Mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci Lett 1990; 114:147-153. (Pubitemid 20188949)
14. Metzger R, Bader M, Ludwig T, et al. Expression of the mouse and rat Mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995; 357: 27-32.
15. Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111:1806-1813. (Pubitemid 40525146)
16. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin(1-7). Peptides 1993; 14:679-684.
17. Burgelova M, Vanourkova Z, Thumova M, et al. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1 -7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009; 27:1988-2000.
18. Dhaunsi GS, Yousif MH, Akhtar S, et al. Angiotensin-(1-7) prevents diabetesinduced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 2010; 638:108-114.
19. Durand MJ, Raffai G, Weinberg BD, Lombard JH. Angiotensin 1-7 and low dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 2010; 299:H1024-H1033.
20. Giani JF, Munoz MC, Mayer MA, et al. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructosefed rats. Am J Physiol Heart Circ Physiol 2010; 298:H1003-H1013.
21. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1 -7). Am J Physiol Heart Circ Physiol 2007; 292:H736-H742.
22. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin -angiotensin system. Hypertension 1998; 31:356-361.
23. Iyer SN, Averiii DB, Chappell MC, et al. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 2000; 36:417-422.
24. Mercure C, Yogi A, Callera GE, et al. Angiotensin(1 -7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319-1326.
25. Nie W, Yan H, Li S, et al. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Mol Immunol 2009; 46:355-361.
26. Wang Y, Qian C, Roks AJ, et al. Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail 2010; 3:286-293.
27. Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55:90-98.
28. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 2010; 298:F579-F588.
29. Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 2009; 296:F337-F346.
30. Eatman D, Wang M, Socci RR, et al. Gender differences in the attenuation of salt-induced hypertension by angiotensin (1 -7). Peptides 2001; 22:927-933. (Pubitemid 32522970)
31. Ebermann L, Spillmann F, Sidiropoulos M, et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur J Pharmacol 2008; 590:276-280.
32. Fraga-Silva RA, Pinheiro SV, Goncalves AC, et al. The antithrombotic effect of angiotensin-(1-7) involves Mas-mediated NO release from platelets. Mol Med 2008; 14:28-35. (Pubitemid 351356883)
33. Gironacci MM, Valera MS, Yujnovsky I, Pena C. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension 2004; 44:783-787. (Pubitemid 39435254)
34. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1 -7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001; 37:72-76. (Pubitemid 32064242)
35. Kozlovski VI, Lomnicka M, Fedorowicz A, Chlopicki S. On the mechanism of coronary vasodilation induced by angiotensin-(1-7) in the isolated guinea pig heart. Basic Clin Pharmacol Toxicol 2007; 100:361-365. (Pubitemid 46776383)
36. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 1994; 111:652-654. (Pubitemid 24151646)
37. Rajendran S, Chirkov YY, Campbell DJ, Horowitz JD. Angiotensin-(1-7) enhances antiaggregatory effects of the nitric oxide donor sodium nitroprusside. J Cardiovasc Pharmacol 2005; 46:459-463. (Pubitemid 41407573)
38. Sampaio WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49:185-192. (Pubitemid 46360359)
39. Zhang Y, Lu J, Shi J, et al. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. Neuropeptides 2008; 42:593-600.
40. Zhi JM, Chen RF, Wang J, et al. Comparative studies of vasodilating effects of angiotensin-(1-7) on the differentvessels. Sheng Li Xue Bao 2004; 56:730-734.
41. Almeida AP, Frabregas BC, Madureira MM, et al. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res 2000; 33:709-713. (Pubitemid 30428611)
42. Brosnihan KB, Li P, Ferrario CM. Angiotensin(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27:523-528. (Pubitemid 26086221)
43. Fernandes L, Fortes ZB, Nigro D, et al. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 2001; 37:703-709. (Pubitemid 32199053)
44. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 1998; 286:403-410. (Pubitemid 28318016)
45. Nakamoto H, Ferrario CM, Fuller SB, et al. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 1995; 25:796-802.
46. Oliveira MA, Fortes ZB, Santos RA, et al. Synergistic effect of angiotensin-(1 - 7) on bradykinin arteriolar dilation in vivo. Peptides 1999; 20:1195-1201. (Pubitemid 29512440)
47. Munoz MC, Giani JF, Dominici FP. Angiotensin-(1-7) stimulates the phos phorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul Pept 2010; 161:1-7.
48. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42:574-579. (Pubitemid 37237356)
49. Tallant EA, McCollum LT, Gallagher PE. Angiotensin-(1-7) reduces Ang II-induced cardiac hypertrophy with an associated increase in the dual-specificity phosphatase 1 (DUSP1 ) [abstract]. Hypertension 2009; 54:e122.
50. Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces MAP kinase activity by upregulation of the dual-specificity phosphatase DUSP1 [abstract]. Hypertension 2009; 54:e35.
51. Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin- converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43:970-976. (Pubitemid 38579900)
52. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006; 290:C420-C426.
53. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008; 295: H2373-H2379.
54. Lin CS, Pan CH, Wen CH, et al. Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. Peptides 2010; 31: 1334-1340.
55. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-2610. (Pubitemid 40740859)
56. Igase M, Strawn WB, Gallagher PE, et al. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289: H1013-H1019. (Pubitemid 41208941)
57. Igase M, Kohara K, Nagai T, et al. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 2008; 31:553-559. (Pubitemid 351597510)
58. Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30:535-541. (Pubitemid 27444228)
59. Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 2007; 3:125-137. (Pubitemid 46860722)
60. Ferreira AJ, Raizada MK. Are we poised to target ACE2 for the nextgeneration of antihypertensives? J Mol Med 2008; 86:685-690.
61. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1 -7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008; 585:303-312.
62. Santos RA, Ferreira AJ, Pinheiro SV, et al. Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs 2005; 14:1019-1031. (Pubitemid 41131653)
63. Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996; 14:799-805. (Pubitemid 26187416)
64. Ferrario CM, Martell N, Yunis C, et al. Characterization ofangiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11:137-146. (Pubitemid 28137604)
65. Schindler C, Brosnihan KB, Ferrario CM, et al. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 2007; 47:112-120. (Pubitemid 44974005)
66. Ferrario CM, Smith RD, Brosnihan B, et al. Effects of omapatrilat on the reninangiotensin system in salt-sensitive hypertension. Am J Hypertens 2002; 15:557-564. (Pubitemid 34596964)
67. Kocks MJ, Lely AT, Boomsma F, et al. Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. J Hypertens 2005; 23:597-602. (Pubitemid 40691197)
68. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiologyto the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59:251-287. (Pubitemid 47481436)
69. Navar LG. The intrarenal renin-angiotensin system in hypertension. Kidney Int 2004; 65:1522-1532. (Pubitemid 38407000)
70. Pendergrass KD, Pirro NT, Westwood BM, et al. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol 2008; 295:H10-H20.
71. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68:2189-2196. (Pubitemid 43117793)
72. Chappel MC, Ferrario CM. ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1 -7). Kidney Int 2006; 70: 8-10. (Pubitemid 44000112)
73. Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. Sci World J 2009; 9:522-535.
74. Koitka A, Cooper ME, Thomas MC, Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 2008; 35:420-425. (Pubitemid 351326772)
75. Lely AT, Hamming I, van Goor H, Navis GJ. Renal ACE2 expression in human kidney disease. J Pathol 2004; 204:587-593. (Pubitemid 39585958)
76. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51:613-623. (Pubitemid 351400834)
77. Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74:1610-1616.
78. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168:1808-1820. (Pubitemid 43825302)
79. Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther 2010; 12:R85.
80. Pignone A, Rosso AD, Brosnihan KB, et al. Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 2007; 66:1305-1310. (Pubitemid 47492472)